BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, Hart AL, Irving PM, Kok KB, Lamb CA, Limdi JK, Macdonald J, McGovern DP, Mehta SJ, Murray CD, Patel KV, Pollok RC, Raine T, Russell RK, Selinger CP, Smith PJ, Bowden J, McDonald TJ, Lees CW, Sebastian S, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.Gut. 2021;70:865-875. [PMID: 33753421 DOI: 10.1136/gutjnl-2021-324388] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Mahmud N, Shah Y, Khan N. Prevalence of SARS-COV-2 Vaccination and Factors Impacting Likelihood of Vaccination in a Nationwide Veterans Affairs Cohort of IBD Patients. Inflamm Bowel Dis 2022:izac083. [PMID: 35397005 DOI: 10.1093/ibd/izac083] [Reference Citation Analysis]
2 Garcillán B, Salavert M, Regueiro JR, Díaz-castroverde S. Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review. Vaccines 2022;10:297. [DOI: 10.3390/vaccines10020297] [Reference Citation Analysis]
3 Sakuraba A, Luna A, Micic D. Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis. Gastroenterology 2022;162:88-108.e9. [PMID: 34599933 DOI: 10.1053/j.gastro.2021.09.055] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I; REsponses to COVid-19 vaccinE IsRaeli IBD group [RECOVERI]. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology 2021:S0016-5085(21)03701-X. [PMID: 34717923 DOI: 10.1053/j.gastro.2021.10.029] [Reference Citation Analysis]
5 Wack S, Patton T, Ferris LK. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence. J Am Acad Dermatol 2021:S0190-9622(21)02217-9. [PMID: 34363909 DOI: 10.1016/j.jaad.2021.07.054] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Amodio D, Ruggiero A, Sgrulletti M, Pighi C, Cotugno N, Medri C, Morrocchi E, Colagrossi L, Russo C, Zaffina S, Di Matteo G, Cifaldi C, Di Cesare S, Rivalta B, Pacillo L, Santilli V, Giancotta C, Manno EC, Ciofi Degli Atti M, Raponi M, Rossi P, Finocchi A, Cancrini C, Perno CF, Moschese V, Palma P. Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies. Front Immunol 2021;12:727850. [PMID: 34671350 DOI: 10.3389/fimmu.2021.727850] [Reference Citation Analysis]
7 Shehab M, Abu-Farha M, Alrashed F, Alfadhli A, Alotaibi K, Alsahli A, Alphonse Thanaraj T, Channanath A, Ali H, Abubaker J, Almulla F. Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study. J Clin Med 2021;10:5362. [PMID: 34830644 DOI: 10.3390/jcm10225362] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mamais I, Malatras A, Papagregoriou G, Giallourou N, Kakouri AC, Karayiannis P, Koliou M, Christaki E, Nikolopoulos GK, Deltas C. Circulating IgG Levels in SARS-CoV-2 Convalescent Individuals in Cyprus. J Clin Med 2021;10:5882. [PMID: 34945178 DOI: 10.3390/jcm10245882] [Reference Citation Analysis]
9 Murthy SK, Kuenzig ME, Windsor JW, Ghia JE, Griffiths AM, Panaccione R, Seow CH, Benchimol EI, Bernstein CN, Bitton A, Huang JG, Jones JL, Lee K, Kaplan GG, Mukhtar MS, Tandon P, Targownik LE, Gibson DL. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines-Biology, Current Evidence and Recommendations. J Can Assoc Gastroenterol 2021;4:S54-60. [PMID: 34755040 DOI: 10.1093/jcag/gwab033] [Reference Citation Analysis]
10 Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, Cope AP, Dasandi T, Graham C, Lechmere T, Malim MH, Meynell F, Pollock E, Seow J, Sychowska K, Barker JN, Norton S, Galloway JB, Doores KJ, Tree TIM, Smith CH. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol 2021;3:e627-37. [PMID: 34258590 DOI: 10.1016/S2665-9913(21)00212-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ruan W, Nguyen H, Wyatt A, Ihekweazu F, Vartabedian BS, Karam L, Walsh S, Kellermayer R. High Seroconversion Rate Against Severe Acute Respiratory Syndrome Coronavirus 2 in Symptomatic Pediatric Inflammatory Bowel Disease Patients. J Pediatr Gastroenterol Nutr 2021;73:363-6. [PMID: 34173793 DOI: 10.1097/MPG.0000000000003211] [Reference Citation Analysis]
12 Manansala M, Chopra A, Baughman RP, Novak R, Lower EE, Culver DA, Korsten P, Drake WP, Judson MA, Sweiss N. COVID-19 and Sarcoidosis, Readiness for Vaccination: Challenges and Opportunities. Front Med (Lausanne) 2021;8:672028. [PMID: 33996868 DOI: 10.3389/fmed.2021.672028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Moutsopoulos HM. A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine. J Autoimmun 2021;121:102649. [PMID: 33984571 DOI: 10.1016/j.jaut.2021.102649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Dailey J, Kozhaya L, Dogan M, Hopkins D, Lapin B, Herbst K, Brimacombe M, Grandonico K, Karabacak F, Schreiber J, Liang BT, Salazar JC, Unutmaz D, Hyams JS. Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease. medRxiv 2021:2021. [PMID: 34159338 DOI: 10.1101/2021.06.12.21258810] [Reference Citation Analysis]
15 Chen RE, Gorman MJ, Zhu DY, Carreño JM, Yuan D, VanBlargan LA, Burdess S, Lauffenburger DA, Kim W, Turner JS, Droit L, Handley SA, Chahin S, Deepak P, O'Halloran JA, Paley MA, Presti RM, Wu GF, Krammer F, Alter G, Ellebedy AH, Kim AHJ, Diamond MS. Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors. Med (N Y) 2021;2:1327-1341.e4. [PMID: 34812429 DOI: 10.1016/j.medj.2021.11.004] [Reference Citation Analysis]
16 Assa A, Benninga MA, Borrelli O, Broekaert I, de Carpi JM, Saccomani MD, Dolinsek J, Mas E, Miele E, Thomson M, Tzivinikos C; Gastrointestinal Committee of ESPGHAN. Gastrointestinal Perspective of Coronavirus Disease 2019 in Children-An Updated Review. J Pediatr Gastroenterol Nutr 2021;73:299-305. [PMID: 34117195 DOI: 10.1097/MPG.0000000000003204] [Reference Citation Analysis]
17 Spencer EA, Klang E, Dolinger M, Pittman N, Dubinsky MC. Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients. Inflamm Bowel Dis 2021;27:1862-4. [PMID: 34427638 DOI: 10.1093/ibd/izab194] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Vollenberg R, Tepasse P, Lorentzen E, Nowacki TM. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study. JPM 2022;12:694. [DOI: 10.3390/jpm12050694] [Reference Citation Analysis]
19 Brosh-Nissimov T, Maor Y, Elbaz M, Lipman-Arens S, Wiener-Well Y, Hussein K, Orenbuch-Harroch E, Cohen R, Zimhony O, Chazan B, Nesher L, Rahav G, Zayyad H, Hershman-Sarafov M, Weinberger M, Najjar-Debbiny R, Chowers M. Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study. Euro Surveill 2022;27. [PMID: 35593161 DOI: 10.2807/1560-7917.ES.2022.27.20.2101026] [Reference Citation Analysis]
20 Doherty J, Fennessy S, Stack R, O' Morain N, Cullen G, Ryan EJ, De Gascun C, Doherty GA. Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic. Aliment Pharmacol Ther 2021;54:1110-23. [PMID: 34472643 DOI: 10.1111/apt.16590] [Reference Citation Analysis]
21 Neurath MF. COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34188251 DOI: 10.1038/s41575-021-00480-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Chhibba T, Targownik LE. Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant? The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00040-1] [Reference Citation Analysis]
23 Nezametdinova VZ, Yunes RA, Dukhinova MS, Alekseeva MG, Danilenko VN. The Role of the PFNA Operon of Bifidobacteria in the Recognition of Host's Immune Signals: Prospects for the Use of the FN3 Protein in the Treatment of COVID-19. Int J Mol Sci 2021;22:9219. [PMID: 34502130 DOI: 10.3390/ijms22179219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, Haile A, Huang K, Kinnett B, Liebeskind MJ, Liu Z, McMorrow LE, Paez D, Perantie DC, Schriefer RE, Sides SE, Thapa M, Gergely M, Abushamma S, Klebert M, Mitchell L, Nix D, Graf J, Taylor KE, Chahin S, Ciorba MA, Katz P, Matloubian M, O'Halloran JA, Presti RM, Wu GF, Whelan SPJ, Buchser WJ, Gensler LS, Nakamura MC, Ellebedy AH, Kim AHJ. Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. medRxiv 2021:2021. [PMID: 33851176 DOI: 10.1101/2021.04.05.21254656] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 20.0] [Reference Citation Analysis]
25 Bakasis AD, Mavragani CP, Boki KA, Tzioufas AG, Vlachoyiannopoulos PG, Stergiou IE, Skopouli FN, Moutsopoulos HM. COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review. J Autoimmun 2021;123:102687. [PMID: 34311142 DOI: 10.1016/j.jaut.2021.102687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Hisamatsu T. Management of inflammatory bowel disease during the COVID-19 pandemic. Immunol Med 2021;:1-8. [PMID: 34530694 DOI: 10.1080/25785826.2021.1978205] [Reference Citation Analysis]
27 Vollenberg R, Tepasse P, Kühn JE, Hennies M, Strauss M, Rennebaum F, Schomacher T, Boeckel G, Lorentzen E, Bokemeyer A, Nowacki TM. Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2. Biomedicines 2022;10:171. [DOI: 10.3390/biomedicines10010171] [Reference Citation Analysis]
28 Khan N, Mahmud N. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications. Gastroenterology 2021;161:827-36. [PMID: 34048782 DOI: 10.1053/j.gastro.2021.05.044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
29 Bosa L, Di Chiara C, Gaio P, Cosma C, Padoan A, Cozzani S, Perilongo G, Plebani M, Giaquinto C, Donà D, Cananzi M. Protective SARS-CoV-2 Antibody Response in Children With Inflammatory Bowel Disease. Front Pediatr 2022;10:815857. [DOI: 10.3389/fped.2022.815857] [Reference Citation Analysis]
30 Ghavami SB, Shahrokh S, Asadzadeh Aghdaei H, Khoramjoo SM, Farmani M, Kazemifard N, Parigi TL, Danese S, Balaii H, Sherkat G, Ebrahimi Daryani N, Alborzi F, Vossoughinia H, Zali MR. Serological response to SARS‐CoV ‐2 is attenuated in patients with inflammatory bowel disease and can affect immunization. JGH Open. [DOI: 10.1002/jgh3.12725] [Reference Citation Analysis]
31 Chanchlani N, Lin S, Chee D, Hamilton B, Nice R, Zehra A, Bewshea C, Cipriano B, Derikx LAAP, Dunlop A, Greathead L, Griffiths RL, Ibraheim H, Kelleher P, Kok KB, Lees CW, MacDonald J, Sebastian S, Smith PJ, McDonald TJ, Irving PM, Powell N, Kennedy NA, Goodhand JR, Ahmad T. Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients. J Crohns Colitis 2021:jjab153. [PMID: 34473254 DOI: 10.1093/ecco-jcc/jjab153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
32 Boekel L, Hooijberg F, Vogelzang EH, Besten YR, Leeuw M, Atiqi S, van Vollenhoven RF, Wijbrandts CA, Gerritsen M, Krieckaert C, Dijkshoorn B, Bakhlakh S, Crooijmans JJ, Voskuyl A, van der Horst-Bruinsma IE, Lems W, Kuijpers TW, van Ham SM, Wieske L, Eftimov F, Kummer LY, van Dam PK, Stalman EW, Steenhuis M, Keijzer S, Cristianawati O, Keijser J, Loeff FC, Tas SW, Nurmohamed MT, Boers M, Rispens T, Wolbink G. Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study. RMD Open 2022;8:e002035. [PMID: 35383121 DOI: 10.1136/rmdopen-2021-002035] [Reference Citation Analysis]
33 Schneider L, Schubert L, Winkler F, Munda P, Winkler S, Tobudic S. SARS-CoV-2 vaccine response in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00405-0. [PMID: 35487452 DOI: 10.1016/j.cgh.2022.04.006] [Reference Citation Analysis]
34 Koletzko L, Klucker E, Le Thi TG, Breiteneicher S, Rubio-Acero R, Neuhaus L, Stark RG, Standl M, Wieser A, Török H, Koletzko S, Schwerd T. Following Pediatric and Adult IBD Patients through the COVID-19 Pandemic: Changes in Psychosocial Burden and Perception of Infection Risk and Harm over Time. J Clin Med 2021;10:4124. [PMID: 34575235 DOI: 10.3390/jcm10184124] [Reference Citation Analysis]
35 Rong JM, Luo J, Huang Q, Miao YL. Individualized selection of biological agents in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(15): 893-900 [DOI: 10.11569/wcjd.v29.i15.893] [Reference Citation Analysis]
36 Törüner M, Kalkan İH, Akyüz F, Tezel A, Çelik AF. Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic. Turk J Gastroenterol 2021;32:488-92. [PMID: 34405814 DOI: 10.5152/tjg.2021.280721] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Esposito S, Antoniol G, Labate M, Passadore L, Alvisi P, Daccò V, Ghizzi C, Colombo C, Principi N. Vaccines in Children with Inflammatory Bowel Disease: Brief Review. Vaccines (Basel) 2021;9:487. [PMID: 34064576 DOI: 10.3390/vaccines9050487] [Reference Citation Analysis]
38 De Greef J, Scohy A, Zech F, Aboubakar F, Pilette C, Gerard L, Pothen L, Yildiz H, Belkhir L, Yombi JC. Determinants of IgG antibodies kinetics after severe and critical COVID-19. J Med Virol 2021;93:5416-24. [PMID: 33945634 DOI: 10.1002/jmv.27059] [Reference Citation Analysis]
39 Levartovsky A, Ben-Horin S. Anti-TNF Therapy During the SARS-CoV-2 Pandemic: Friend or Foe? J Crohns Colitis 2021:jjab167. [PMID: 34626174 DOI: 10.1093/ecco-jcc/jjab167] [Reference Citation Analysis]
40 Farhangnia P, Dehrouyeh S, Safdarian AR, Farahani SV, Gorgani M, Rezaei N, Akbarpour M, Delbandi A. Recent Advances in Passive Immunotherapies for COVID-19: The Evidence-Based Approaches and Clinical Trials. International Immunopharmacology 2022. [DOI: 10.1016/j.intimp.2022.108786] [Reference Citation Analysis]
41 Clarke K, Pelton M, Stuart A, Tinsley A, Dalessio S, Bernasko N, Williams ED, Coates M. COVID-19 Vaccine Hesitancy in Patients with Inflammatory Bowel Disease. Dig Dis Sci. [DOI: 10.1007/s10620-021-07377-5] [Reference Citation Analysis]
42 Suresh L. Update on COVID-19 vaccines and autoimmune-mediated rheumatic diseases. Reumatologia 2021;59:203-5. [PMID: 34538949 DOI: 10.5114/reum.2021.108395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Rodríguez-Martinó E, Medina-Prieto R, Santana-Bagur J, Santé M, Pantoja P, Espino AM, Sariol CA, Torres EA. Early immunologic response to mRNA COVID-19 vaccine in patients receiving biologics and/or immunomodulators. medRxiv 2021:2021. [PMID: 34545370 DOI: 10.1101/2021.09.11.21263211] [Reference Citation Analysis]
44 Li X, Tong X, Wong ICK, Peng K, Chui CSL, Lai FTT, Wan EYF, Wong CKH, Leung WK, Chan EWY. Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study. Gut 2022:gutjnl-2021-326860. [PMID: 35135842 DOI: 10.1136/gutjnl-2021-326860] [Reference Citation Analysis]
45 Dailey J, Kozhaya L, Dogan M, Hopkins D, Lapin B, Herbst K, Brimacombe M, Grandonico K, Karabacak F, Schreiber J, Liang BT, Salazar JC, Unutmaz D, Hyams JS. Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab207. [PMID: 34528661 DOI: 10.1093/ibd/izab207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Alexander JL, Powell N; British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group. SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change? Lancet Gastroenterol Hepatol 2021;6:528-9. [PMID: 34048723 DOI: 10.1016/S2468-1253(21)00184-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
47 Wellens J, Edmans M, Obolski U, McGregor CG, Simmonds P, Turner M, Jarvis L, Skelly D, Dunachie S, Barnes E, Eyre DW, Colombel JF, Wong SY, Klenerman P, Lindsay JO, Satsangi J, Thompson CP. Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease. Gut 2021:gutjnl-2021-326312. [PMID: 34911744 DOI: 10.1136/gutjnl-2021-326312] [Reference Citation Analysis]
48 Chappell H, Patel R, Driessens C, Tarr AW, Irving WL, Tighe PJ, Jackson HJ, Harvey-Cowlishaw T, Mills L, Shaunak M, Gbesemete D, Leahy A, Lucas JS, Faust SN, de Graaf H. Immunocompromised children and young people are at no increased risk of severe COVID-19. J Infect 2021:S0163-4453(21)00548-X. [PMID: 34785268 DOI: 10.1016/j.jinf.2021.11.005] [Reference Citation Analysis]
49 Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, Irving PM, Kamperidis N, Kok KB, Lamb CA, Macdonald J, Mehta S, Pollok RC, Raine T, Smith PJ, Verma AM, Jochum S, McDonald TJ, Sebastian S, Lees CW, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut 2021:gutjnl-2021-324789. [PMID: 33903149 DOI: 10.1136/gutjnl-2021-324789] [Cited by in Crossref: 9] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
50 Wei J, Matthews PC, Stoesser N, Maddox T, Lorenzi L, Studley R, Bell JI, Newton JN, Farrar J, Diamond I, Rourke E, Howarth A, Marsden BD, Hoosdally S, Jones EY, Stuart DI, Crook DW, Peto TEA, Pouwels KB, Walker AS, Eyre DW; COVID-19 Infection Survey team. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. Nat Commun 2021;12:6250. [PMID: 34716320 DOI: 10.1038/s41467-021-26479-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Marmitt DJ. Potential plants for inflammatory dysfunction in the SARS-CoV-2 infection. Inflammopharmacology 2022. [PMID: 35389124 DOI: 10.1007/s10787-022-00981-5] [Reference Citation Analysis]
52 Alexander JL, Kennedy NA, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Liu Z, Nice R, Bewshea C, D'mello A, Constable L, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HRT, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Boyton RJ, Goodhand JR, Hart AL, Lees CW, Ahmad T, Powell N, Chukwurah I, Haq S, Shah P, Wilken-smith S, Ramanathan A, Patel M, Romanczuk L, King R, Domingo J, Shamtally D, Mendoza V, Sanchez J, Stark H, Knight B, Bee L, Estember C, Barnes A, Watkins D, Stone S, Kirkwood J, Parkinson M, Gardner-thorpe H, Covil K, Derikx L, Gros Alcalde B, Lee I, Cipriano B, Ruocco G, Baden M, Cooke G, Pollock K. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00005-x] [Reference Citation Analysis]
53 Kaplan GG, Ma C, Charlton C, Kanji JN, Tipples G, Sharifi N, Herauf M, Coward S, Ingram RJM, Hracs L, Benchimol EI, Panaccione R. Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study. Gut 2021:gutjnl-2021-325238. [PMID: 34340997 DOI: 10.1136/gutjnl-2021-325238] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
54 Ray K. Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD. Nat Rev Gastroenterol Hepatol 2021;18:286. [PMID: 33785883 DOI: 10.1038/s41575-021-00445-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Fresco-taboada A, García-durán M, Aira C, López L, Sastre P, van der Hoek L, van Gils MJ, Brouwer PJ, Sanders RW, Holzer B, Zimpernikc I, López-collazo E, Muñoz P, Rueda P, Vela C. Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination. Diagnostic Microbiology and Infectious Disease 2022. [DOI: 10.1016/j.diagmicrobio.2022.115650] [Reference Citation Analysis]
56 Coward S, Windsor JW, Kuenzig ME, Bitton A, Bernstein CN, Jones JL, Khanna R, Lee K, Murthy SK, Targownik L, Benchimol E, Huang JG, Mukhtar MS, Tandon P, Kaplan GG. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Epidemiology-The Trends of Disease Over Time. J Can Assoc Gastroenterol 2021;4:S20-6. [PMID: 34755035 DOI: 10.1093/jcag/gwab029] [Reference Citation Analysis]
57 Lanari M, Venturini E, Pierantoni L, Stera G, Castelli Gattinara G, Esposito SMR, Favilli S, Franzoni E, Fusco E, Lionetti P, Maffeis C, Marseglia G, Massella L, Midulla F, Zanobini A, Zecca M, Villani A, Staiano A, Galli L; Other Collaborators. Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement. Ital J Pediatr 2022;48:7. [PMID: 35022088 DOI: 10.1186/s13052-021-01187-1] [Reference Citation Analysis]
58 Nakase H, Hayashi Y, Hirayama D, Matsumoto T, Matsuura M, Iijima H, Matsuoka K, Ohmiya N, Ishihara S, Hirai F, Abukawa D, Hisamatsu T; J-COSMOS group. Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS). J Gastroenterol 2022. [PMID: 35089397 DOI: 10.1007/s00535-022-01851-1] [Reference Citation Analysis]
59 Prentice RE, Rentsch C, Al-Ani AH, Zhang E, Johnson D, Halliday J, Bryant R, Begun J, Ward MG, Lewindon PJ, Connor SJ, Ghaly S, Christensen B. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. GastroHep 2021;3:212-28. [PMID: 34539248 DOI: 10.1002/ygh2.473] [Reference Citation Analysis]
60 Veisman I, Lederer NB, Ukashi O, Kopylov U, Klang E. Top 25 cited articles on Covid-19 and IBD: A bibliometric analysis. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101959] [Reference Citation Analysis]
61 Wong SY, Dixon R, Martinez Pazos V, Gnjatic S, Colombel JF, Cadwell K; ICARUS-IBD Working Group. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. Gastroenterology 2021;161:715-718.e4. [PMID: 33887219 DOI: 10.1053/j.gastro.2021.04.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
62 Abhishek A, Boyton RJ, McKnight Á, Coates L, Bluett J, Barber VS, Cureton L, Francis A, Appelbe D, Eldridge L, Julier P, Peckham N, Valdes AM, Rombach I, Altmann DM, Nguyen-Van-Tam J, Williams HC, Cook JA. Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study). BMJ Open 2022;12:e062599. [PMID: 35504634 DOI: 10.1136/bmjopen-2022-062599] [Reference Citation Analysis]
63 Cannatelli R, Ferretti F, Carmagnola S, Bergna IMB, Monico MC, Maconi G, Ardizzone S. Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD. Gut 2021:gutjnl-2021-326237. [PMID: 34819330 DOI: 10.1136/gutjnl-2021-326237] [Reference Citation Analysis]
64 Shire ZJ, Reicherz F, Lawrence S, Sudan H, Golding L, Majdoubi A, Levett PN, Lavoie PM, Jacobson K. Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy. Gut 2021:gutjnl-2021-326196. [PMID: 34815272 DOI: 10.1136/gutjnl-2021-326196] [Reference Citation Analysis]
65 Becchetti C, Broekhoven AGC, Dahlqvist G, Fraga M, Zambelli MF, Ciccarelli O, Saouli AC, Trizzino A, Banz V, Dufour JF, Roukens AHE, Torres Morales SP, Myeni SK, Kikkert M, Feltkamp MCW, Coenraad MJ. Humoral response to SARS-CoV-2 infection among liver transplant recipients. Gut 2022:gutjnl-2021-326609. [PMID: 34987065 DOI: 10.1136/gutjnl-2021-326609] [Reference Citation Analysis]
66 Li K, Feng C, Chen H, Feng Y, Li J. Trends in Worldwide Research in Inflammatory Bowel Disease Over the Period 2012–2021: A Bibliometric Study. Front Med 2022;9:880553. [DOI: 10.3389/fmed.2022.880553] [Reference Citation Analysis]